# Open-label Extension Study of ADP101

> **NCT05243719** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alladapt Immunotherapeutics, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Food Allergy

## Interventions

- **BIOLOGICAL:** ADP101

## Key facts

- **NCT ID:** NCT05243719
- **Lead sponsor:** Alladapt Immunotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-14
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-02-27
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243719, "Open-label Extension Study of ADP101". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05243719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*